K Street's federal lobbying reports were due last week, and OpenSecrets is back with some initial numbers.
The U.S. Chamber of Commerce spent the most on lobbying federal lawmakers, increasing its spending by 58% from 2008 as it stepped up efforts to defeat climate change and health care legislation. $79.2 million—more than half of its $144.5 million in 2009 lobbying expenditures—were made in the final three months of the year.
The health care debate also intensified lobbying efforts. PhRMA, the pharmaceutical industry trade group, spent $26 million and Pfizer, Amgen, and Eli Lilly spent a combined $45 million. That's a lot of money, and so far it seems to have worked. The reform bill has stalled with the election of senator Scott Brown (R-Mass.) and Senator Chris Dodd recently proposed taking a break from the issue. While insurance and pharmacutical companies increased their lobbying bucks, AARP dropped its spending by nearly 25% and SEIU increased its lobbying dollars only modestly, by 8% (about $200,000).
Energy companies also poured money into lobbying as Congress dithered over cap-and-trade legislation. From 2008 to 2009, Chevron upped spending by 60%, ConocoPhillips by 114%, and BP by 53%.
The OpenSecrets report doesn't delve into lobbying numbers from the big banks, but The Hill points out that during the financial crisis in 2009, eight of the nation's largest banks spent nearly $26 million lobbying lawmakers. On the whole, Bank of America, Goldman Sachs, and Citigroup decreased or maintained their lobbying sums from 2008 to 2009. Bank of America, however, began "pouring in more money" during the fourth quarter, reports McClatchy. Lobbying sums from the financial services sector are only expected to grow as industry groups intensify their opposition to impending financial regulation.